The HIV-1 capsid protein makes up the core of the virion and plays a critical role in early 2 steps of HIV replication. Due to its exposure in the cytoplasm after entry, HIV capsid is a 3 target for host cell factors that act directly to block infection such as TRIM5 and MxB. 4 Several host proteins also play a role in facilitating infection, including in the protection 5 of HIV-1 capsid from recognition by host cell restriction factors. Through an unbiased 6 screening approach, called HIV-CRISPR, we show that the Cyclophilin A-binding 7 deficient P90A HIV-1 capsid mutant becomes highly-sensitized to TRIM5alpha restriction 8 in IFN-treated cells. Further, the CPSF6-binding deficient, N74D HIV-1 capsid mutant is 9 sensitive to restriction mediated by human TRIM34, a close paralog of the well-10 characterized HIV restriction factor TRIM5. This restriction occurs at the step of reverse 11 transcription, is independent of interferon stimulation and limits HIV-1 infection in key 12 target cells of HIV infection including CD4+ T cells and monocyte-derived dendritic cells. 13 TRIM34 restriction requires TRIM5alpha as knockout or knockdown of TRIM5alpha 14 results in a loss of antiviral activity. TRIM34 can also restrict some SIV capsids. Through 15 immunofluorescence studies, we show that TRIM34 and TRIM5alpha colocalize to 16 cytoplasmic bodies and are more frequently observed to be associated with infecting 17 N74D capsids than with WT capsids. Our results identify TRIM34 as an HIV-1 CA-18 targeting restriction factor and highlight the potential role for heteromultimeric TRIM 19 interactions in contributing restriction of HIV-1 infection in human cells.
Introduction
The HIV-1 capsid protein (CA or p24gag) forms the core of the virion and is key to Interferon-Stimulated Genes (ISGs), the PIKAHIV library, was infected with wildtype or the N74D 15 or P90A capsid mutant viruses after overnight treatment with Interferon. Two possibilities are 16 that these mutants are either more sensitive to the same restrictions that target wild type 17 capsids or that they are sensitive to novel capsid-targeting restriction factor(s).
18
Cell pellets and viral supernatants were collected and both genomic DNA from cells and For the N74D capsid mutant screen we find a novel HIV-1 restriction factor, TRIM34, as 3 the highest-scoring hit that is not found in the screen with wildtype HIV-1 ( Figure 1C : Green).
4
TRIM34 scores as highly as the IFN pathway genes ( Figure 1C : Magenta), highlighting the key 5 role TRIM34 plays in blocking replication of the N74D capsid mutant virus. TRIM34 was first 6 described to be an Interferon-Stimulated Gene in HeLa cells (Orimo et al., 2000) and is in a 7 cluster of paralogous human TRIM genes that includes TRIM5alpha, TRIM22 and TRIM6 on 2B). Further confirming these findings, we repeated the PIKAHIV screen in THP-1 cells without 8 any IFN treatment and find TRIM34 as a significant hit (data not shown).
9
We also determined whether or not TRIM34 plays a role in restriction of HIV-1 capsids in 10 primary activated, CD4+ T cells. TRIM34 KO CD4+ T cell pools were generated through 11 electroporation of CD3/CD28-activated CD4+ T cells with CRISPR/Cas9 complexes targeting 12 TRIM34 or NTC. 62% of TRIM34 alleles were found to be edited in this experiment ( Figure 2C ).
13
We infected the control and TRIM34-KO pools with both wild type and the N74D capsid mutant The N74D CA mutant virus was first characterized due to its loss of CPSF6 binding (Lee 5 et al., 2010). Therefore, we reasoned that loss of CPSF6 binding could expose HIV-1 CA to 6 restriction by TRIM34. To ask if the loss of CPSF6 binding is sufficient to sensitize HIV-1 7 capsids to TRIM34 restriction, we tested another CPSF6-binding capsid mutant A77V that, like 8 N74D, also results in loss of binding to CPSF6 (Saito et al., 2016) . In contrast to infection with 9 N74D CA we find that infection of TRIM34-overexpressing cells is equivalent to wild type cells 10 for the A77V mutant ( Figure 3A) . We further tested the relative sensitivity of N74D and A77V in 11 primary cells by knocking out TRIM34 in primary, activated CD4+ T cells ( Figure 3B ). We 12 measured infection of these cells by the N74D and A77V CA mutants as compared to a wild 13 type control ( Figure 3B ). As shown in Figure 2 , infection with the N74D CA mutant can be 14 rescued by TRIM34 knockout in CD4+ T ( Figure 3B ). Consistent with our overexpression assay 15 in THP-1 cells we find that the A77V mutant is not rescued by TRIM34 knockout in CD4+ T cells 16 ( Figure 3B ). Therefore, in both THP-1 cells and primary CD4+ T cells the A77V mutant that lacks binding to CPSF6 does not become sensitive to TRIM34 restriction. Therefore, restriction Figure 3D ). Therefore, human TRIM34 retrovirus restriction activity is not 29 limited to HIV-1 CA mutants, as TRIM34 restricts at least two SIV strains in addition to the HIV-1
TRIM34 restriction requires TRIM5alpha
1 TRIM34 is a close paralog of TRIM5alpha which is known to dimerize and form higher-2 order oligomers (Ganser-Pornillos and Pornillos, 2019). Furthermore, TRIM34 has been shown 3 to be able to interact with TRIM5alpha in cells both in a yeast two-hybrid assay (Zhang et al., loop (see Figure 1D ), a region shown to be critical for mediating specificity of capsid recognition 
11
To ask if TRIM5alpha is important for restriction of the N74D capsid mutant virus, we 12 compared the ability of TRIM34 to restrict the N74D virus in cells both with and without 13 TRIM5alpha. We introduced a TRIM5alpha or Control CRISPR/Cas lentiviral vector into THP-1 the N74D capsid mutant is lost when TRIM5 is missing ( Figure 4A) . In contrast, we see no effect of TRIM34 overexpression or TRIM5-KO in THP-1 cells infected with the WT capsid ( Figure 4B 
21
To ask if this requirement of TRIM5alpha for restriction of the N74D virus by TRIM34 is also important in primary cells, we knocked out either TRIM34 or TRIM5alpha in primary CD4+ 23 cells and infected each cell pool with WT, N74D or P90A CA mutant viruses in comparison to a 24 control cell pool ( Figure 4C ). Indeed, consistent with a requirement of TRIM5 for the TRIM34-25 medicated restriction, we find that knockout of either TRIM34 or TRIM5 is sufficient to rescue 26 infection with the N74D capsid mutant ( Figure 4C) while neither knockdown has a significant 27 effect on WT HIV-1 infection ( Figure 4C ). We also examined this question in primary monocyte-28 derived dendritic cells (MoDCs) by transducing them with shRNA lentiviral vectors, resulting in 29 stable knockdown of TRIM34 (TRIM34 KD) or TRIM5alpha (TRIM5 KD) ( Figure 4D ). In addition,
30
to more directly ask if TRIM34 and TRIM5alpha work together or synergistically, we challenged 31 cells in which both TRIM34 and TRIM5alpha were depleted simultaneously (TRIM5/TRIM34
In contrast, knockdown of either TRIM34 or TRIM5alpha does not have any effect on wild type 1 HIV-1 capsids ( Figure 4E ). Further, TRIM34 and TRIM5alpha act in the same pathway, rather 2 than synergistically, to inhibit the N74D capsid mutant since a double-knockdown in MoDCs 3 does not show any additional rescue ( Figure 4D ).
4
Finally, we asked if TRIM5alpha restriction of the CypA-binding deficient P90A mutant 5 depends on TRIM34. Consistent with the results of our initial screen with the P90A mutant 6 ( Figure 1B) , we find that HIV-1 P90A is sensitive to TRIM5alpha restriction ( Figure 4C : CD4+ T 7 Cells; Figure 4F : MoDCs). However, this restriction activity is independent of TRIM34 as 8 TRIM34 knockout or knockdown has little to no effect on the P90A virus ( Figure 4C : CD4+ T 9 Cells; Figure 4F : MoDCs). These data suggest that TRIM34 restriction depends on TRIM5alpha, 10 but that TRIM5alpha restriction does not depend on TRIM34. Therefore, there is asymmetry in 
18
HIV-1 or the N74D CA mutant and 2 hours later colocalization of TRIM34 or both TRIM34 and
19
TRIM5alpha with each capsid was compared. Given that TRIM34 restricts N74D capsids but not 20 the WT virus, we hypothesized that this differential restriction could be due to specific 21 localization of TRIM34 to N74D HIV-1 capsids that does not occur, or does not occur to the same extent, as with wild type HIV-1 capsids. TRIM34 localizes to cytoplasmic puncta, 23 commonly referred to as cytoplasmic bodies, similar to TRIM5alpha (Figure 5A -"Mock"; red -24 TRIM34, green -TRIM5alpha). Indeed, we observed colocalization of TRIM34 with HIV-1 25 capsids in the cell cytoplasm ( Figure 5A : compare "WT" to "N74D" -white arrowheads).
26
Quantification of the number of p24+ puncta that are also positive for TRIM34 shows that 27 colocalization of TRIM34 with p24 occured more frequently for N74D capsids than for WT 28 capsids ( Figure 5B ). As TRIM34 restriction of the N74D capsid mutant requires TRIM5alpha, we 29 also quantified the degree to which TRIM34 colocalizes with TRIM5alpha in cells. We assayed 30 the subcellular localization of both TRIM34 and TRIM5alpha in HeLa cells stably-overexpressing 31 both YFP-TRIM5alpha and HA-TRIM34. We observe significant colocalization of TRIM34 and N74D capsid mutant cores as compared to WT cores ( Figure 5C ). Therefore, TRIM34 and 1 TRIM5 are present together with incoming N74D HIV-1 capsids in the cytoplasm of infected The antiviral activity of TRIM34 is independent of the ability of viral capsids to bind CPSF6 as shown with the CPSF6-binding deficient capsid mutant, A77V, that is not restricted by TRIM34. Figure 1B ) but rather is due to restriction by a novel 21 capsid-targeting restriction factor, TRIM34. TRIM34 is a close paralog of the well-studied capsid-targeting restriction factor TRIM5alpha. Previously, modest restriction of SIVmac by 23 human TRIM34 was described but no effect of TRIM34 was observed on either wild type HIV-1 24 or a G98V capsid mutant virus (Zhang et al., 2006) . Our data suggest that TRIM34, together 25 with TRIM5alpha, mediates all or most of the block to replication of the N74D capsid mutant 26 observed in primary cells, including CD4+ T cells and MDMs, first described by Ambrose et al.
27
(Ambrose et al., 2012).
28
The site that sensitizes HIV-1 capsid to TRIM34 restriction, N74, is highly-conserved 29 across HIV-1 and SIV strains (Lee et al., 2010) . Mutations at this site may sensitize capsids to 30 TRIM34/TRIM5 restriction and therefore have been selected against. However, this effect is 31 independent of CPSF6 binding to capsids as loss of binding to CPSF6 is not sufficient for cells (Bulli et al., 2016) . Therefore, our data support a model in which CPSF6 binding plays a targeting restrictions. In contrast, loss of CypA binding sensitizes HIV-1 capsids to TRIM5alpha 4 restriction (Kyusik's paper). However, loss of CypA binding is not sufficient for TRIM5alpha 
17
TRIM5alpha knockout or knockdown rescues the HIV-1 P90A capsid mutant in human 18 primary cells suggesting that at least one function of CypA binding is evasion of TRIM5alpha-19 mediated restriction (Kyusik's paper here). Our screening data show with the P90A mutant did 20 not uncover an additional factor other than TRIM5, suggesting that the increased IFN sensitivity 
24
Of particular interest, we find that TRIM34 restriction depends on TRIM5alpha. More does this restriction depend on TRIM5alpha? We propose two potential models that are 1 consistent with our data that are not mutually exclusive. First, it is possible that TRIM34 2 changes the specificity of TRIM5alpha such that it can now recognize the N74D capsid mutant 3 virus better and/or more efficiently. TRIM34 can bind to HIV-1 capsids through its SPRY domain 4 (Li et al., 2007; Yang et al., 2014) . However, when compared to TRIM5alpha, human TRIM34 5 has a deletion in the v1 loop of the SPRY domain that is important for determining capsid 6 binding specificity. Further, TRIM34 is not itself evolving under positive selection, an 7 evolutionary signature that would be consistent with a direct protein interface with a viral 8 pathogen. Instead, it may be that the TRIM34 SPRY does not itself make significant contact with 9 the N74D capsid but that TRIM34 complexing with TRIM5alpha may affect recognition of this 10 capsid specifically by human TRIM5alpha.
11
A second possibility is that TRIM34 stabilizes TRIM5alpha, thereby allowing it to restrict cells, TRIM34 is significantly more stable (Li et al., 2007) . It may be that TRIM34 stabilizes 20 TRIM5alpha, thereby allowing it to restrict HIV capsids that transit differently than wild type into 21 the nucleus. In this model, wild type HIV-1 capsids are not sensitive to restriction as they transit the cytoplasm more efficiently and/or via a different nuclear entry route that allows escape from 23 restriction. As proposed by Sultana et al., an accelerated rate of uncoating could be a 24 mechanism of escape from cellular restrictions, particularly those that target the HIV-1 capsid 25 (Sultana et al., 2019) .
26
Either of these models are sufficient to explain why TRIM34 is required for restriction of later edited CD4+ T cell pools were infected with GFP reporter HIV-1 viruses (WT, N74D or P90A) and infection levels assayed 2 days later by flow cytometry. The relative infection is normalized to the average infection in the control cells for each virus. Error bars indicate standard deviation from the mean from triplicate infections. D, E and F: Monocyte-derived dendritic cells were simultaneously transduced with a lentiviral vector encoding shRNAs targeting TRIM34 or luciferase control (Luc) and the other shRNA vector specific for TRIM5 or Luc, for the knockdown as indicated. The pooled cells were challenged with VSV-G pseudotyped HIV-1 vectors expressing GFP reporter and containing CA-N74D (D), WT CA (E), or CA-P90A (F), across a range of viral inputs. The percentage of GFP-positive cells was determined 2 days later by flow cytometry.
Figure 5. TRIM34 colocalizes more frequently with the restricted HIV-1 N74D capsid.
HeLa cells were transduced to express YFP-TRIM5alpha (green) and HA-TRIM34 stably. They were plated on coverslips and synchronously infected with VSV-G pseudotyped HIV-1 with WT or N74D capsids as indicated. At 2 hpi, cells were fixed and stained for viral capsid protein p24 (blue) and HA-TRIM34 tag (red). 15 images were collected per condition in three independent biological replicates. A: Representative images for mock-infected cells (top row), WT-infected cells (middle row), and N74D-infected cells (bottom row). Areas of colocalization between TRIM34 and TRIM5 are indicated by triangles, and triple colocalization between TRIM24, TRIM5 and p24 are indicated by arrows in the zoomed in images for each channel. B: Quantification of percent p24 colocalizing with TRIM34 for the WT and N74D virus. P value was determined by an unpaired t test. Error bars represent SEM of all images collected across three biological replicates for each condition. C: Quantification of percent p24 colocalizing with both TRIM34 and TRIM5alpha for the WT and N74D virus. p value was determined by an unpaired t test. Error bars represent of all images collected across three biological replicates for each condition. 
